The evidence that CERK/C1P acts as a molecular effector of the antiproliferative action of 1,25-dihydroxivitamin D3 represents a new possible target for anticancer therapy of human neuroblastoma and may help to identify new biomarkers for increased disease-specific risks in vitamin D3-deficient patients [93]. This evidence concerns the gene CERK and neuroblastoma.